Related Experiment Video
Updated: Mar 8, 2026

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
Reply: Combining Clinical Trial and Patient Registry Data in Cystic Fibrosis: Who Should Be Compared?
Gregory S Sawicki1,2, Michael W Konstan3,
11 Boston Children's Hospital Boston, Massachusetts.
No abstract available in PubMed .
More Related Videos
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
08:58Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression
Published on: April 18, 2025
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Clinical Trials: Overview
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.